Get the Stockscreener App
134.19
0.92%
-1.24
Illumina Inc stock is traded at $134.19, with a volume of 2.94M.
It is down -0.92% in the last 24 hours and down -0.12% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$135.43
Open:
$137.1
24h Volume:
2.94M
Relative Volume:
1.54
Market Cap:
$20.50B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
30.06
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
-10.46%
1M Performance:
-0.12%
6M Performance:
+36.32%
1Y Performance:
+8.04%
1-Day Range:
$133.33
$140.65
1-Week Range:
$133.33
$150.32
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
134.19 | 20.69B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
565.22 | 214.19B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
219.53 | 153.11B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
642.94 | 50.51B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
132.98 | 37.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
202.54 | 34.70B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics - Yahoo! Finance Canada
Multi-Omics Market Set for Explosive Growth to USD 33.25 Billion - openPR.com
San Diego Zoo’s Frozen Zoo Gets Genomic Boost - 101.5 KGB
Synthetic Biology Market Set for Explosive Growth to USD 67.47 - openPR.com
Mediolanum International Funds Ltd Makes New $914,000 Investment in Illumina, Inc. $ILMN - MarketBeat
Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What Catalysts Are Shifting The Illumina (ILMN) Story For 2026 And Beyond - Yahoo Finance
Illumina, Inc. and the San Diego Zoo Wildlife Alliance Partner to Sequence the Frozen Zoo - marketscreener.com
Illumina Partners with San Diego Zoo for Genomic Sequencing of Endangered Species - Intellectia AI
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally - PR Newswire
WCM Investment Management LLC Has $384.17 Million Position in Illumina, Inc. $ILMN - MarketBeat
Bioinformatics Market to Witness Massive Growth by 2033: - openPR.com
Mapping the future of whole-genome sequencing with Illumina constellation technology - Illumina
Video: UK Festival of Genomics & Biodata 2026 - Illumina
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Canada
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Illumina completes acquisition of SomaLogic - marketscreener.com
Illumina buys SomaLogic in bid to expand proteomics reach - The Pharma Letter
ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance - Nasdaq
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
Does CMS Backing of TruSight Oncology Recast Illumina’s (ILMN) Clinical Genomics Potential? - simplywall.st
PacBio Completes Sale of Short-Read Sequencing Assets to Illumina for $48.1 Million - Quiver Quantitative
Illumina acquires SomaLogic - Medical Buyer
Thrivent Financial for Lutherans Sells 38,212 Shares of Illumina, Inc. $ILMN - MarketBeat
Exosome Research Market to Witness Stunning Growth 2026-2033 - openPR.com
DNA Sequencing Market Covering Prime Factors and Competitive - openPR.com
Y Intercept Hong Kong Ltd Cuts Stock Position in Illumina, Inc. $ILMN - MarketBeat
Cancer Biopsy Market Set for Rapid Growth and Trend by 2026-2033 - openPR.com
Illumina, Inc. $ILMN Position Trimmed by AE Wealth Management LLC - MarketBeat
Metagenomic Sequencing Market to Reach US$ 9.25 Billion by 2033 - openPR.com
Assessing Illumina (ILMN) Valuation As Shares Rebound But Long Term Returns Remain Under Pressure - Yahoo Finance
Can Illumina Inc stock outperform in a bear marketJuly 2025 PostEarnings & Verified Swing Trading Watchlists - baoquankhu1.vn
Understanding the Setup: (ILMN) and Scalable Risk - Stock Traders Daily
Illumina, Inc. $ILMN Position Reduced by Bank of New York Mellon Corp - MarketBeat
Keybank National Association OH Purchases 60,375 Shares of Illumina, Inc. $ILMN - MarketBeat
Standard BioTools completes sale of SomaLogic to Illumina for $350 million - Investing.com Nigeria
Boulder biotech SomaLogic acquired in deal worth up to $425M - The Business Journals
Standard BioTools Completes Sale of SomaLogic to Illumina - Investing News Network
Illumina completes acquisition of SomaLogic for $350 million - Investing.com
Standard BioTools Inc. Completes $350 Million Sale of SomaLogic to Illumina, Enhancing Financial Position for Growth Strategy - Quiver Quantitative
Illumina (NASDAQ: ILMN) completes $350M SomaLogic proteomics deal - Stock Titan
SomaLogic Partnership Resource Hub - Illumina
Impact Partnership Wealth LLC Makes New $744,000 Investment in Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
The Truth About Illumina Inc.: Is This DNA Giant Still Worth Your Money or Is the Hype Over? - AD HOC NEWS
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
New Horizons in Microfluidic Market Booming with Rapid Growth Through 2033 |Agilent Technologies, Inc., Illumina, Inc. - openPR.com
Illumina (ILMN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Illumina, Inc. $ILMN Shares Sold by Mutual of America Capital Management LLC - MarketBeat
Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products - TradingView
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.19%
9.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):